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Abstract
Purpose Expression of members of the calpain system are associated with clinical outcome of patients with, amongst others, 
breast and ovarian cancers, with calpain-2 expression in ovarian cancer being implicated in chemo-resistance and survival. 
This study aimed, using a large patient cohort and in vitro models, to verify its importance and further investigate the role 
in ovarian cancer chemoresponse.
Methods Calpain-1, calpain-2, calpain-4 and calpastatin expression were evaluated in primary ovarian carcinomas (n = 575) 
by immunohistochemistry. Protein expression was assessed, via western blotting, in five ovarian cancer cell lines with various 
sensitivities towards cisplatin/carboplatin. In vitro calpain activity was inhibited by calpeptin treatment to assess changes 
in platinum sensitivity by proliferation assay, with expression of genes associated with epithelial–mesenchymal transition 
being examined by  RT2 Profiler™ PCR Array.
Results The current study confirmed previous data that high calpain-2 expression is associated with poor overall survival 
(P = 0.026) and that calpain-1 was not associated with overall survival or progression-free survival. Low expression of 
calpastatin (P = 0.010) and calpain-4 (P = 0.003) were also associated with adverse survival. Such prognostic associations 
do not seem to be linked with altered tumour sensitivity towards platinum-based chemotherapy. Interestingly, low calpain-1 
expression was more frequent in patients with confined tumours (stage 1) (χ2 = 11.310, df = 1, P = 0.001). Calpain and cal-
pastatin expression varied among ovarian cancer cell lines yet their expression levels were similar between chemo-sensitive 
cells and resistant counterparts. Moreover, calpeptin treatment did not alter cellular response to platinum-based chemotherapy 
or epithelial–mesenchymal transition-related gene expression.
Conclusions The conventional calpains and calpastatin have been confirmed to play an important role in ovarian cancer; 
however, the precise mechanisms whereby they exert effects remain to be elucidated.
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Introduction
Calpains, calcium-dependent papain-like enzymes, are 
cytoplasmic neutral cysteine proteases that regulate 
various cellular processes, such as signal transduction, 
cytoskeletal organisation, cell survival and cell death; 
via cleavage of numerous substrates (Storr et al. 2011a). 
Although there are 16 calpains, the ubiquitously expressed 
conventional calpain subunits are the most widely studied. 
Conventional calpains include micro-calpain (µ-calpain) 
and milli-calpain (m-calpain), which are functional heter-
odimeric calpains. The heterodimer consists of one calpain 
large subunit, i.e. calpain-1 or calpain-2 and a common 
small subunit, i.e. calpain-4 (Storr et al. 2011a). The acti-
vation of the conventional calpains is tightly controlled by 
multiple mechanisms including calcium influx, the relative 
abundance of calpain subunits and of their endogenous 
inhibitor, calpastatin (Zhang et al. 2017).
The relationship between the expression of the calpain 
system in cancer and patient outcome has been examined 
in a number of studies. Whether expression and outcomes 
are significantly associated or whether the associations 
were positive or negative seems to depend on context, such 
as tumour type, subtype and heterogeneity (Storr et al. 
2011b, c, 2012a, b; Al-Bahlani et al. 2017). By comparing 
matched chemo-sensitive and chemo-resistant cell lines, 
calpains have been suggested to be an important protein 
family involved in the cellular response to chemotherapy. 
Calpain-2 has been found to be overexpressed both at the 
mRNA and protein levels in chemo-resistant colon can-
cer HT-29R cells in comparison with the parental line 
(Fenouille et al. 2012). Calpain activity was significantly 
higher in cisplatin-resistant MeWo-cis1 cells than in the 
parental MeWo cells (Młynarczuk-Biały et al. 2006), and 
calpain-4 expression was shown to be significantly lower 
in cisplatin-resistant gastric cancer SGC-7901/DDP and 
BGC-823/DDP cells than in parental cells (Zhang et al. 
2016).
As indicated above, aberrant expression, or activity, of 
the calpain system occurs in various cancers. Yet very lit-
tle information is available regarding the association of 
calpains and calpastatin expression with clinicopathologi-
cal factors and prognosis in ovarian cancer. Salehin et al., 
(2011) indicated that calpastatin expression levels were 
lower in ovarian tumours compared to normal tissues, 
whilst high calpain-1 expression was linked with lower 
tumour grade; with low calpain-2 expression being linked 
with increased lymph node metastasis. Yang et al. (2017) 
found a negative association between calpain-4 expression 
and overall survival with high calpain-4 expression signifi-
cantly associated with the presence of lymph node metas-
tasis (P = 0.009) and high FIGO stage (P = 0.001, n = 91). 
In a previously published study by our group (n = 154 
patients), high calpain-2 expression was significantly 
associated with platinum resistance (χ2 = 4.658, df = 1, 
P = 0.031), poor progression-free survival (P = 0.049) 
and poor overall survival (P = 0.006) (Storr et al. 2012a). 
High expression was significantly associated, in mul-
tivariate analysis, accounting for grade, stage, optimal 
debulking and platinum sensitivity, with worse OS (haz-
ard ratio = 2.174; 95% confidence interval = 1.144–4.130; 
P = 0.018) (Storr et al. 2012a). The current study, using a 
larger patient cohort and including calpain-4 expression, 
aimed to verify such results and to use in vitro experimen-
tal models to examine potential regulatory mechanisms.
Materials and methods
Clinical samples
The ovarian tissue microarray was composed of tumour 
cores from 575 ovarian cancer cases; with 448 chemo-
naïve samples and 22 cases sampled post-chemotherapy 
(no chemotherapy details were available on the remainder). 
Staging was according to the International Federation of 
Obstetrics and Gynecology (FIGO) staging system. Grad-
ing was performed using the Shimizu–Silverberg grading 
system. The clinicopathological variables of the cohort 
are listed in Table 1. Patients were diagnosed with ovar-
ian cancer and received treatment at Nottingham University 
Hospitals between 1991 and 2011. The median follow-up 
period was 8 years: ranging between 3 years and 20 years. 
The median overall survival time was 44 months: ranging 
from 0 to 223 months. The majority of the patients (n = 357) 
received platinum-based chemotherapy among which 168 
patients were treated with chemotherapy containing taxa-
nes (Table S1). Progression-free survival was defined as the 
length of time between start of treatment and clinical identi-
fication of recurrence. Data on the resistance to chemother-
apy were recorded, classified by the Gynaecologic Oncology 
Group (GOG) as either refractory (not responding to chemo-
therapy), resistant (an initial response to chemotherapy with 
recurrence within 6 months) or sensitive (when there was 
either no recurrence or recurred after 6 months). Ethical 
approval was obtained from Derbyshire Ethics Committee 
(07/H0401/156). This study is reported in accordance with 
REMARK (reporting recommendations for tumour marker 
prognostic studies) criteria (McShane et al. 2005).
Tissue microarray, immunohistochemistry 
and interpretation
Protein expression was investigated using sections taken 
from tissue microarray blocks, which were constructed as 
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follows. Tumour samples had been immediately fixed in 10% 
formalin and embedded into paraffin blocks. Donor blocks 
were sectioned and stained with haematoxylin and eosin 
with a specialist gynaecological pathologist reviewing and 
marking the area of interest to core. A Beecher instrument 
manual tissue microarrayer was used to produce the TMA 
paraffin blocks by extracting cores of 0.6 mm from the donor 
blocks and placing them in pre-punched holes in the TMA 
blocks, each with approximately 160 cores. For the majority 
of the cases, a single tissue core was used for each patient. 
There were 48 cases that had two cores per case and 3 that 
had three cores per case. A small number of cores from other 
tissues were also placed in each TMA block to act as poten-
tial subsequent positive controls and to aid orientation. Fresh 
sections (4 µm) were cut from each block and placed on 
coated glass slides for the immunohistochemical assessment 
of protein expression.
Immunohistochemistry was performed as described 
previously (Storr et al. 2012a), following re-optimisations. 
Briefly, slides were heated at 60 °C for 10 min then dewaxed 
in xylene and rehydrated in industrial methylated spirits. 
Sections were pre-treated by heat-induced epitope retrieval 
in 0.01  mol/L sodium citrate buffer, pH 6, for 10  min 
(750W) + 10 min (450W) in a microwave oven. Staining 
was achieved using a Novolink Polymer Detection System 
(Leica, Denmark) following the manufacturers’ instructions. 
Briefly, endogenous peroxidase activity was neutralised with 
peroxidase block reagent for 5 min at room temperature; 
followed by application of protein block reagent for 5 min 
at room temperature, to minimise non-specific interactions 
of the subsequent detection reagents after washing with 
Tris buffered saline. Primary antibody was diluted in bond 
primary antibody diluent (Leica, Denmark) and applied to 
the tissue overnight at 4 °C. The primary antibodies were 
diluted in bond primary antibody diluent (Leica, Denmark), 
calpain-1 (1:1000, Santa Cruz Biotechnology, INC.), cal-
pain-2 (1:2500,  Chemicon® International Millipore), cal-
pain-4 (1:100,000,  Chemicon® International Millipore) and 
calpastatin antibody (1:50,000,  Chemicon® International 
Millipore), and applied to the tissue overnight at 4 °C. The 
specificity of these antibodies was initially confirmed, by 
western blotting, before use. Post-primary reagent, a pol-
ymer penetration enhancer, was applied on the slides for 
30 min; followed by NovoLink Polymer [anti-mouse/rab-
bit IgG-Poly- horseradish peroxidase (HRP)] for another 
30 min, with each step followed by a Tris buffered saline 
wash. Immunohistochemical reactions were visualised with 
3, 3′-diaminobenzidine (DAB) for 5 min and counterstained 
with haematoxylin for 6 min. Slides were then dehydrated 
with industrial methylated spirits and xylene and mounted 
with DPX (SIGMA). Negative controls had primary anti-
body omitted.
Slides were scanned at high resolution using a Nano-
zoomer Digital Pathology Scanner (Hamamatsu Photon-
ics) with 200× magnification. Staining intensity was semi-
quantitatively assessed using an immunohistochemical 
H-score with ranking from none (0), weak (1), medium (2) 
to strong (3) with the percentage area of each staining inten-
sity being multiplied by the intensity rank (H-score range: 
0–300). Greater than 25% of the slides were examined by 
a second independent assessor blinded to scores and clin-
icopathologic criteria. Single measure intraclass correla-
tion coefficient (ICC) analysis was used to determine the 
Table 1  Clinicopathologic variables of patient cohort
Variables Number of 
Patients
Percentage (%)
Age
 ≤ 62 295 52.4
 > 62 268 47.6
Histological subtypes
 HGSC 337 59.7
 Mucinous carcinoma 60 10.6
 Endometrioid carcinoma 68 12.1
 CCC 53 9.4
 LGSC 30 5.3
 SBOT 15 2.7
Grade
 1 48 8.5
 2 90 16.0
 3 425 75.5
Stage
 I 203 36.7
 II 64 11.6
 III 245 44.3
 IV 41 7.4
Residual disease
 No residual tumour 311 62.2
 Residual tumour (< 2 cm) 58 11.6
 Residual tumour (> 2 cm) 131 26.2
Adjuvant therapy
 Pt-based chemotherapy 357 63.3
 Non-platinum-based chemotherapy 6 1.1
 No chemotherapy 80 14.2
 Information not available 121 21.5
Response to chemotherapy
 Refractory and resistance 66 17.7
 Sensitivity 307 82.3
Progression status
 No recurrence 137 32.9
 Recurred 280 67.1
Survival status
 Living 234 42.0
 Deceased 323 58.0
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level of agreement between independent scorers. The single 
measure ICCs between scores were 0.8, 0.814, 0.733 and 
0.796 for calpain-1, calpain-2, calpain-4 and calpastatin 
protein expression, respectively. A non-biased cut-point of 
the immunohistochemical scores, to dichotomise data, was 
determined using X-tile software using patient OS (Camp 
et al. 2004; Storr et al. 2012a).
Cell culture
Ovarian cancer cell lines PEO1 and PEO4 cells were 
obtained from the American Type Culture Collection. 
A2780, A2780-cis and SKOV-3 cells were obtained from 
the European Collection of Authenticated Cell Cultures. 
Cells were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 medium (SIGMA) (for A2780 and A2780-
cis), RPMI medium (SIGMA,) containing Sodium Pyru-
vate (SIGMA) 2 mM (for PEO1 and PEO4) or McCoy’s 5A 
Modified medium (SIGMA) (for SKOV-3) supplemented 
with 10% heat-inactivated iron-supplemented donor bovine 
serum (Gibco, Life Technologies) and penicillin/streptomy-
cin (SIGMA) (with 10,000 units penicillin and 10 mg strep-
tomycin/mL) in 37 °C and 5%  CO2 atmosphere. Cisplatin 
(1 µM) was added to A2780-cis culture media every two 
to three passages. Cell line authentication was conducted 
using the Promega  Powerplex® 16-short-tandem-repeat sys-
tem. All cell lines were regularly screened for mycoplasma 
infection using a  MycoProbe® Mycoplasma Detection Kit 
(R&D Systems). Cells in logarithmic growth phase were 
used for experiments.
Drug preparation
Stock solution of cisplatin (p4394, SIGMA) was made 
at 1 mg/ml in sodium chloride solution (0.9%) (S8776, 
SIGMA). Carboplatin (c2538 SIGMA) was initially diluted 
in sterile distilled water  (dH2O) to reach 20 mM. Both 
stock solutions were protected from light, stored at room 
temperature and used within 2 months. Calpeptin (03-34-
0051, Merck Millipore) was initially diluted to 100 mM in 
dimethyl sulfoxide (DMSO, D2650, SIGMA), and then the 
aliquoted stock solution was stored at − 20 °C.
Western blotting
Subconfluent cells were trypsinised, washed, collected and 
lysed at 5 × 106 cells per ml in RIPA buffer (R0278, SIGMA) 
supplemented with 1 × Halt Protease Inhibitor Cocktail 
containing protease inhibitors, phosphatase inhibitors and 
EDTA (ThermoFisher Scientific) at 4 °C for 10 min and 
then lysates were frozen at − 20 °C or − 70 °C for long-term 
storage.
Cell lysate was loaded into SDS-PAGE gel (Novex® 
ready-made  NuPAGE® 4–12% Bis-Tis Protein Gels), after 
which proteins were separated by gel electrophoresis and 
transferred onto a 0.2-µm nitrocellulose membrane (Mil-
lipore). Membranes were then blocked with 3% non-fat 
milk PBS containing 0.1% Tween 20 prior to incubation 
with primary antibody overnight at 4 °C. Antibodies were 
used at the following dilutions: anti-calpastatin 1:1000, anti-
calpain-1 1:1000, anti-calpain-2 1:2500 and anti-calpain-4 
1:1000. Membranes were washed and incubated with mouse/
rabbit anti-β-actin antibody [1 in 1000 dilution, ab8226 or 
ab8227 (Abcam)], for 1 h at room temperature. Secondary 
antibodies [i.e. 680 Donkey anti-Mouse IgG (H + L) (926-
32222,  IRDye®, LI-COR) and 800CW Donkey anti-Rabbit 
IgG (H + L) (926-32213,  IRDye®, LI-COR)] were incubated 
on the membrane for 1 h. Membranes were visualised using 
an Odyssey FC Imager (LI-COR Biosciences). The fluores-
cence intensity was quantified using Image Studio Version 
4.0. (LI-COR Biosciences) and normalised against β-actin 
signals.
Evaluation of cell proliferation and chemosensitivity
SKOV-3, PEO1 and PEO4 cells were used to assess effects 
of calpain inhibition on cell proliferation and chemosensi-
tivity. To ensure cells were in log phase during assessment, 
2 ml of cell suspension (8 × 104/ml SKOV3 cells, 1 × 105/
ml PEO1 cells and 1 × 105/ml PEO4 cells) were seeded into 
each well of six-well plates. Cells were plated for variable 
times before treatment, according to particular doubling 
times. SKOV3 and PEO1 cells were cultured for 1 day whilst 
PEO4 cells for 3 days before treatment. Doubling time for 
SKOV3’s was 32.3 ± 4.0 h, for PEO1 57.4 ± 5.7 h and for 
PEO4 102.7 ± 8.5 h (data not shown). Cells were then pre-
treated for 1 h (SKOV3) or 90 min (PEO-1 and -4) with 
50 µM calpeptin followed by an additional 48-h treatment 
with cisplatin (SKOV3: 5 µM, PEO1: 3 µM, PEO4: 19 µM) 
or carboplatin (SKOV3: 11  µM, PEO1: 14  µM, PEO4: 
26 µM) (IC50 concentrations) in the presence of 50 µM cal-
peptin. Cells in each well were trypsinised and counted at 
various times thereafter.
RNA extraction and real‑time EMT PCR array
PEO-1/-4 cells were treated with DMSO or 50 µM calpep-
tin for 4 h or 24 h based on calpain activity results from 
fluorescent plate reader assays using a fluorescent substrate 
CMAC, t-BOC-Leu-Met, which indicated that 50 µM cal-
peptin induced maximal inhibition over a 90 min–48 h 
treatment time (approximately 30% for PEO1 and 40% for 
PEO4) (data not shown). Total RNA was extracted from 
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treated cells with RNA protect Cell Reagent (Qiagen) and 
purified with the RNeasy Plus Mini Kit (Qiagen) accord-
ing to the manufacturer’s instructions. RNA samples from 
three independent experiments were pooled together. After 
quantification using a Nanodrop spectrophotometer (calcu-
lation of 260/280 nm ratio), 0.5 µg total RNA was reversed 
transcribed into cDNA using  RT2 First Strand Kit (Qia-
gen) at 42 °C for 15 min following by 95 °C for 5 min 
to stop the reaction. Real-time PCR was performed using 
the Human Epithelial to Mesenchymal Transition (EMT) 
 RT2 Profiler™ PCR Array (PAHS-090Z, Qiagen) in com-
bination with  RT2 SYBR Green Mastermixes (Qiagen). 
The PCR array profiles the expression of 84 key genes 
involved in EMT process. The PCR cycling condition was 
set as follows: 95 °C for 10 min, 40 cycles of 95 °C for 
15 s and 60 °C for 1 min and run on ABI-7500 (Applied 
Biosystems). Data were analysed using the ΔΔCt method.
Statistical analysis
The relationships between categorised protein expression 
and clinicopathologic factors were examined using Pear-
son’s chi-square test of association (χ2) or Fisher’s exact 
test if a cell count was less than 5 in a 2 × 2 table. To 
assess the relationship between protein expression and sur-
vival outcomes, survival curves were generated using the 
Kaplan–Meier method and statistical significance deter-
mined by the Log-rank test. Multivariate survival analysis 
was performed using a proportional hazards model by Cox 
regression analysis to estimate hazard ratios and 95% con-
fidence intervals for overall survival. Spearman’s rank cor-
relation coefficient (Spearman’s rho) test was performed 
to assess the correlation between the expression levels of 
different proteins. The correlation strength was interpreted 
as follows: Spearman rho (rs) less than 0.16 is too weak 
to be meaningful, ranging from 0.16 to 0.19 as very weak 
correlation, 0.20 to 0.39 as a weak correlation, 0.40 to 
0.59 as a moderate correlation, and 0.60 to 0.79 as strong 
correlation, and 0.80 or greater as very strong correlation 
(Divaris et al. 2012). Results from in vitro experiments 
were represented as average ± standard deviation from a 
minimum of three independent experiments. For compar-
ing two variables, the Student’s t test was used and one-
way ANOVA was used to compare three or more groups. 
Statistical analyses were carried out using SPSS 22.0 soft-
ware. P values < 0.05 were considered statistically signifi-
cant. Data analysis of the PCR array was carried out using 
the online GeneGlobe Data Analysis Centre. Fold-change 
of target genes against the reference gene was calculated 
from  2−△△Ct values. The CT cut-off was set at 35. Gene 
expression differences greater than twofold were consid-
ered as differentially transcribed.
Results
Expression pattern of the calpain system in ovarian 
cancer
Calpain-1, -2, -4 and calpastatin expression was confined 
to the membrane and cytoplasm (Fig. 1). Calpains and 
calpastatin showed predominant granular/diffuse staining 
in the cytoplasm of the ovarian cancer cells with heteroge-
neity between adjacent tumour cells, varying from weak to 
intense staining. Some stromal cell staining was observed; 
however, this was not scored as part of this study.
There were 98 cases common to both the current and the 
previously reported cohort (Storr et al. 2012a). Although 
tissues were from the same cases, different positions of the 
respective primary tumour were sampled for each of the 
two cohorts. Average protein expression from the previ-
ous study was compared with the protein expression in 
matched cases from the current cohort using Spearman’s 
correlation test. Calpastatin and calpain-1 expression lev-
els were significantly correlated with each other in these 
two studies (rs = 0.602, P < 0.001, n = 67 and rs = 0.512, 
P < 0.001, n = 69 respectively). No correlation between 
calpain-2 expression in these two studies (rs = 0.179, 
P = 0.141, n = 69) was observed suggesting potential het-
erogeneity of expression of the calpain system in tumours.
Calpain system expression and clinicopathological 
factors
High calpastatin expression was observed in 256 (55%) 
out of 469 cases (cut-point: 80). Pearson’s chi-squared 
test was performed to evaluate the relationships between 
the expression of calpain system and clinicopathologic 
characteristics with results shown in Table 2. High cal-
pastatin expression was associated with younger patients 
(χ2 = 4.955, df = 1, P = 0.026) and high-grade serous car-
cinoma (HGSC) (χ2 = 17.403, df = 5, P = 0.004) whilst 
low calpastatin expression was linked with clear-cell 
carcinoma (CCC). This association between calpastatin 
and ovarian subtype was also significant in chemo-naïve 
samples (χ2 = 15.958, df = 5, P = 0.007).
High calpain-1 expression was observed in 368 (79%) 
of the 469 available cases (cut-point: 55); whereas, high 
calpain-2 expression was observed in 379 (81%) of the 469 
available cases (cut-point: 10). Low calpain-1 expression 
was linked with low stage (χ2 = 15.259, df = 3, P = 0.002), 
no residual disease (χ2 = 15.388, df = 2, P < 0.001), CCC, 
endometrioid and mucinous carcinoma (χ2 = 56.577, df = 5, 
P < 0.001) whilst high calpain-1 expression was linked 
with the presence of residual disease and HGSC (Table 2). 
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Based on tumour stage, patients were grouped according 
to whether they had an organ-confined tumour (i.e. group 
1: stage 1 and group 2: stage 2–4) or according to whether 
they had distant metastasis (i.e. group 1: stage 1–3 and 
group 2: stage 4). Calpain-1 showed a significant asso-
ciation with organ-confined ovarian cancers rather than 
cancers with distant metastases, with low calpain-1 more 
frequent in organ-confined ovarian cancers (χ2 = 11.310, 
df = 1, P = 0.001). Significant associations between cal-
pain-1 expression and ovarian subtype (χ2 = 46.754, df = 5, 
P < 0.001), stage (χ2 = 17.449, df = 3, P = 0.001) and 
residual disease (χ2 = 14.723, df = 2, P = 0.001) were also 
detected in chemo-naïve samples.
High calpain-4 expression was observed in 326 (70%) out 
of 469 available cases (cut-point: 95). HGSC was associ-
ated with high calpain-4 expression whilst CCC with low 
calpain-4 expression (χ2 = 18.181, df = 5, P = 0.003). This 
association between calpain-4 and ovarian subtype was also 
significant in chemo-naïve samples (χ2 = 15.420, df = 5, 
P = 0.009) (Table 2).
Calpain system expression and clinical outcomes
High calpain-2 expression was significantly associated with 
adverse overall survival (P = 0.026) while high calpain-4 and 
calpastatin expression were significantly associated with bet-
ter overall survival (with P = 0.003 and P = 0.010 respec-
tively) (Fig. 2). No significant association was found between 
calpain-1 expression and overall survival (P = 0.153), and 
no association was detected between protein expression and 
progression-free survival (Fig. 3). As all cases (n = 154) 
in the previous study received carboplatin-based adjuvant 
chemotherapy, a log-rank test was conducted in cases from 
the current cohort who received carboplatin-based adjuvant 
chemotherapy (n = 352) using the same cut-point calculated 
from the whole cohort. High calpain-2 was associated with 
poor overall survival (P = 0.030) but not progression-free 
survival (P = 0.381). Calpastatin, calpain-1 and calpain-4 
expression were not associated with either overall survival 
(P = 0.129, 0.080 and 0.060, respectively) or progression-
free survival (P = 0.181, 0.161 and 0.470, respectively) (data 
not shown).
With P values from the log-rank test of less than 0.001, 
age, grade, FIGO stage, histological subtypes, tumour resi-
due and platinum sensitivity were included in multivariate 
analysis. Neither calpastatin nor calpain-2/-4 was found as 
independent markers of overall survival (Table 3).
Correlations between calpain‑1, ‑2, and ‑4 
and calpastatin expression
Spearman’s rho test was used in assessing the correlation 
between matched H-scores of conventional calpain subu-
nits and calpastatin. Calpastatin, and calpain-1, -2 and 
-4 expression were found positively correlated with each 
other (Table S2). Tumours were then recategorised accord-
ing to expression of any two of calpain-1, -2, and -4, and 
calpastatin into four groups each time; for example, using 
calpain-1 and -2 expression the recategorised groups are: 
tumour with low expression of both calpain-1 and -2; tumour 
with high expression of both calpain-1 and -2; tumour with 
low calpain-1 and high calpain-2 expression; tumour with 
high calpain-1 and low calpain -2 expression. Significant 
associations were observed between overall survival and all 
the combined expression statuses except the combination of 
calpain-1 and calpain-2 expression (P = 0.092; Fig. 4) with 
none significant from multivariate analysis when conducted 
as above.
Calpain expression and overall survival in patient 
subgroups
Further analysis was conducted to investigate the prognostic 
significance of conventional calpains and calpastatin in the 
individual subgroups defined by clinicopathologic variables. 
The P values of Kaplan–Meier survival analysis are sum-
marised in Table S3 with none of the associations statisti-
cally significant at a P value of 0.001 (set lower due to the 
multiple testing).
As chemotherapy treatment may induce changes in pro-
tein expression in tumours, associations between protein 
expression and survival outcome were analysed in 448 cases 
that were chemo-naïve. Calpain-4 (P = 0.030) and calpasta-
tin (P = 0.022) expression were significantly associated with 
overall survival; however, the association between calpain-2 
expression and overall survival was no longer significant 
(P = 0.532) (data not shown).
Calpain and calpastatin expression in vitro 
and effects of calpeptin on chemoresponse
To determine if platinum sensitivity could be modulated by 
altering calpain activity in vitro five ovarian cell lines, with 
varying sensitivities to platinum-based agents, were used. 
Protein expression was initially assessed by western blot-
ting (Fig. 5). PEO1 and PEO4 cells expressed higher lev-
els of calpain-1 and -4, and calpastatin than the other three 
cell lines. Notably, no significant difference was observed 
Fig. 1  Representative photomicrographs of calpains and calpastatin 
expression in ovarian carcinoma cells. Expression levels, including 
low (left), medium (middle) and high (right) staining, of a calpasta-
tin, b calpain-1, c calpain-2 and d calpain-4 in the cytoplasm at × 10 
magnification with × 20 magnification inset panel. Scale bar repre-
sents 100 µm
◂
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between platinum-sensitive cell lines (i.e. A2780 and PEO1) 
and their resistant counterparts (i.e. A2780-cis and PEO4 
respectively). A2780 and A2780-cis cells expressed very 
low levels of calpain system proteins (Fig. 5) and were more 
sensitive to calpain inhibition, i.e. at the 48-h time point, 
IC50 of A2780 and A2780-cis cells were 58 µM and 68 µM 
whilst IC50 of SKOV3, PEO1 and PEO4 cells were 86 µM, 
82 µM and 154 µM. Chemo-sensitisation studies were, there-
fore, conducted using SKOV3, PEO1 and PEO4 cells.
Calpain activity was modulated using the widely used 
calpain inhibitor calpeptin (Thorpe et al. 2015; Hou et al. 
2012). As shown in Fig. 6, use of calpeptin did not alter 
platinum-based chemotherapy response, as assessed by pro-
liferation, in any of the cell lines used.
Effect of calpain activity on EMT‑related gene 
expression
RT2 Profiler PCR Arrays were used to investigate EMT 
(epithelial–mesenchymal transition)-related gene expres-
sion profiles of PEO1 and PEO4 cells. The comparison 
of gene expression patterns were first assessed in vehicle 
control PEO1 and PEO4 cells at 4-h/24-h time point; and 
then vehicle control group was compared with the respective 
calpeptin-treated group at each time point in each cell line. 
When comparing PEO4 with PEO1, BMP7 and COL3A1 
genes were shown to be highly differentially expressed 
(BMP7: 259.84 at 4-h and 351.79 at 24-h–fold, respectively; 
COL3A1: 75.56 at 4-h and 107.55 at 24-h–fold, respec-
tively), whereas JAG1 and WNT5A genes were expressed in 
lower levels (JAG1: − 11.73 at 4-h and − 7.15 at 24-h–fold, 
respectively; WNT5A: -13.74 and − 10.28, respectively). 
Other differently expressed genes are listed in Table S4. 
Differences in EMT-related gene expression between vehi-
cle control groups and calpeptin-treated groups were, how-
ever, relatively small (fold-change < 10) and may be open 
to greater variations (threshold cycle > 30). A partial list of 
the differentially expressed (≥ twofold) EMT-related genes 
is presented in Table S5.
Discussion
In the previously published study by our group (n = 154), 
high levels of calpain-2 expression were significantly associ-
ated with platinum resistance (χ2 = 4.658, df = 1, P = 0.031), 
adverse progression-free survival (P = 0.049) and overall 
survival (P = 0.006) (Storr et al. 2012a), with significance 
associated with overall survival maintained in multivari-
ate analysis including grade, stage, optimal debulking and 
platinum sensitivity (hazard ratio = 2.174; 95% confidence 
interval = 1.144–4.130; P = 0.018) (Storr et al. 2012a). The 
current study, using a larger cohort (n = 575), confirms that Pt
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high calpain-2 expression is significantly associated with 
worse overall survival (P = 0.026). In both studies, calpain-1 
was not significantly associated with either progression-
free survival (P = 0.503) or overall survival (P = 0.153). A 
significant association between calpastatin expression and 
overall survival was observed in the current study but not 
the previous one.
µ-Calpain and m-calpain are isozymes, with their large 
subunits, calpain-1 and calpain-2, sharing the same regula-
tory subunit calpain-4 (Murachi et al. 1990). From survival 
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analysis, significant associations were observed between 
overall survival and the combined expression status, except 
the combination of calpain-1 and calpain-2 expression 
(P = 0.092; Fig. 4). These findings suggest that the role 
that calpain-1 plays may not be complementary to those of 
calpain-2.
Although calpain-1 expression was not associated with 
patient survival, low calpain-1 expression showed signifi-
cant association with organ-confined status of tumour in the 
current study. Similar findings were reported by Al-Bahlani 
et al. (2017) in triple-negative breast cancers; calpain-1 
expression was not significantly associated with patient out-
come (n = 55) but significant association was found between 
calpain-1 expression and the lymph node status (P = 0.02). 
Significant association has been observed between tumour 
metastasis (i.e. vessel invasion, presence of lymph node 
metastasis and/or advanced tumour-node-metastasis stage) 
and the expression of conventional calpain subunits or cal-
pastatin (Yang et al. 2017; Salehin et al. 2011; Storr et al. 
2011b); however, it is context dependent on whether the 
association was positive or negative. Since stage reflects the 
extent of ovarian tumour spread in vivo, calpain-1 may be 
involved in tumour migration and invasion in vitro. Calpain-
mediated proteolysis is involved in focal adhesion dynamics 
and migration in vitro, as reviewed by Franco and Hutten-
locher (2005); however, research in this area lacks informa-
tion on in vivo calpain substrates related to focal adhesions 
and detachment (Perrin and Huttenlocher 2002). In contrast 
to our previous data, calpain-2 was not associated with PFS 
(Fig. 3), whilst calpain-4 and calpastatin was associated 
with OS (P = 0.003 and P = 0.010 respectively) (Fig. 2). All 
cases (n = 154) included in the previous study received car-
boplatin-based adjuvant chemotherapy, thus Kaplan–Meier 
survival analysis was conducted in 352 cases from the cur-
rent cohort who received carboplatin-based adjuvant chemo-
therapy. Again, high calpain-2 was associated with poor OS 
but no significant association was found between calpain-2 
expression and PFS.
The lack of association between calpain-2 and patient 
response to platinum-based chemotherapy, in the current 
study, may be due to the variability of polyclonal antibodies 
between different batches and/or due to the different com-
position of patients. The percentage of platinum-sensitive 
patients was different between the previous cohort (67.5%) 
and the current cohort (82.3%). Patients were then divided 
into platinum-resistant and platinum-sensitive groups, and 
log-rank test was conducted in these two groups separately. 
Conventional calpain subunits and calpastatin did not show 
significant association with OS in either of these two groups 
(data not shown). By Pearson’s chi-squared test, neither 
conventional calpain subunits nor calpastatin was associ-
ated with the resistance to platinum-based adjuvant chem-
otherapy in the current study. Thus, some in vitro studies 
were conducted to help explain the potentially contradictory 
findings.
Fenouille and colleagues observed different calpain 
expression levels between the chemo-resistant cells and their 
parental counterparts (Fenouille et al. 2012); however, in the 
current in vitro study, chemo-sensitive ovarian cancer cells 
(i.e. A2780 and PEO1 cells) and their resistant counterparts 
(i.e. A2780-cis and PEO4 cells, respectively) expressed 
similar levels of calpain-1, -2, and -4, and calpastatin. Thus, 
the cisplatin resistance of A2780-cis and PEO4 cells may not 
be calpain related. In the current study, cells were pre-treated 
with calpeptin and then exposed to cisplatin or carboplatin. 
Comparing against cisplatin or carboplatin treatment alone, 
no altered chemo-sensitisation was detected using cell prolif-
eration as an endpoint. The role of the calpain in regulating 
chemosensitivity is complex and rather confused. Cisplatin 
has, in different cancer types, been shown in certain stud-
ies to induce apoptosis in a calpain-dependent manner (e.g. 
melanoma and cervical cancer cells, Del Bello et al. 2013; 
Shen et al. 2016), with some potentially contradictory find-
ings suggesting that calpain inhibitors can chemo-sensitise 
certain cancer cells (e.g. colorectal cancer, Fenouille et al. 
2012) with others, in hepatoblastoma models (Kim et al. 
2007), suggesting that calpains are not among the main regu-
lators of chemotherapy-induced cell death. In ovarian can-
cer cell lines, calpain activation has been shown to increase 
following a cisplatin-induced increase of  Ca2+ levels in 
OV2008 cells (Al-Bahlani et al. 2011; Woo et al. 2012), 
whilst in C13* cells (the resistant counterpart of OV2008 
cells), Al-Bahlani and colleagues (Al-Bahlani et al. 2011) 
observed a cisplatin-induced  Ca2+ level increase and calpain 
activation, whereas Woo and colleagues (Woo et al. 2012) 
detected no increased calpain activity.
Recent studies have suggested that the calpain system 
can play an important role in the process of EMT. In lung 
cancer cells, for example, transforming growth factor-β1 
was showed to induce EMT via calpain-1 (Tan et al. 2017) 
and in melanoma cells calpain-4 knockdown was able to 
Fig. 2  Kaplan–Meier survival curves of calpastatin and calpain-1, 
-2 and -4 expression, and overall survival. Survival analysis shows 
significantly better (P = 0.010) overall survival for ovarian cancer 
patients whose tumours express high calpastatin compared to those 
with tumours expressing low calpastatin. There were no differences 
in overall survival between patients with tumours expressing high cal-
pain-1 and those with tumours expressing low calpain-1 (P = 0.153). 
Survival analysis showed significantly better (P = 0.026) overall sur-
vival for ovarian cancer patients whose tumours expressed low cal-
pain-2 compared to those with tumours expressing high calpain-2. 
Survival analysis also showed significantly better (P = 0.003) overall 
survival for patients with tumours expressing high calpain-4 com-
pared to those expressing low calpain-4. Significance was determined 
using the log-rank test. The tables shown below the Kaplan–Meier 
survival curves listed the number of patients at risk at the specific 
months. High expression—black line, low expression—grey line
◂
 Journal of Cancer Research and Clinical Oncology
1 3
Fig. 3  Kaplan–Meier survival curves of calpastatin and calpain-1, -2 
and -4 expression, and progression-free survival. Analysis of progres-
sion-free survival shows the impact of calpastatin, and calpain-1, -2 
and -4 in ovarian cancer patients. Significance was determined using 
the log-rank test. The tables shown below the Kaplan–Meier survival 
curves listed the number of patients at risk at the specific months. 
High expression—black line, low expression—grey line
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decrease cell migration and invasion (Wang et al. 2017). 
Current IHC and in vitro data suggested that the calpain 
system did not have a major role in chemosensitivity, so the 
role in regulation of EMT was assessed by expression profil-
ing as alterations to this process may have had a role to play 
in mediating the decreased OS seen in the patient samples. 
Calpain inhibition did not cause a large alteration of EMT-
related gene expression in ovarian cancer cell lines PEO1 
and PEO4 cells. In consideration of the limited fold-change, 
further verification of the link between calpain activation 
and EMT-related gene expression needs to be conducted.
One note of caution, to consider, is the limited inhibi-
tion achieved by calpeptin, which could be a potential issue 
of the lack of significant changes in chemosensitivity and 
EMT-related gene expression of calpeptin-treated cells when 
compared to the vehicle controls. Calpeptin is a widely used 
calpain inhibitor. In colorectal cancer cell lines, calpeptin 
(30 min 100 µM treatment) significantly caused more than 
50% inhibition of calpain activity (Thorpe et al. 2015). 
Autolysis of calpain-1 (i.e. activation) could be significantly 
suppressed by calpeptin (50 µM for 30 min) in MCF-7 (Hou 
et al. 2012). Calpeptin (50 µM for 12 h) was also found able 
to effectively inhibit calpain-induced IκBα depolymerisation 
in MCF7 cells (Kim et al. 2010). Immunoblotting results 
indicated that calpeptin (40 µM for 24 h) effectively inhib-
ited calpain activity, and protected filamin A and androgen 
receptor from cleavage by calpain in human prostate can-
cer cell lines PC-3 (Liu et al. 2014). Such data suggest that 
40–100 µM calpeptin treatment for at least 30 min could 
effectively inhibit calpain activity and calpain-induced pro-
tein cleavage. In the current study, a commonly used dose 
of 50 µM calpeptin induced a 30–40% inhibition with wide 
variation and increasing the dose did not increase inhibition 
but did start to induce cytotoxic effects (data not shown).
As PEO1 was derived from ascitic fluid of a patient with 
ovarian adenocarcinoma whilst PEO4 was derived from 
the ascites of the same patient at the time of relapse the 
COL3A, and BMP7 differential expression, in the current 
study, may be of interest in terms of tumour progression. 
Very limited high-throughput screening studies have been 
conducted on EMT-related proteins in relation to ovarian 
cancer. A similar tendency, as seen in the current study, 
with COL3A1 protein was seen in a previous study in that 
expression was higher in a highly proliferative ovarian 
carcinoma cell line than in a low malignant potential one 
(Gagné et al. 2007). COL3A1 gene has also been found 
differentially expressed between primary ovarian carci-
nomas and metastases (Li et al. 2017). Le Page and col-
leagues showed that BMP2 was differentially transcribed 
between cells derived from ascites and solid tumours (Le 
Page et al. 2006) whilst Hibbs and colleagues suggested 
BMP7 was more highly expressed in ovarian carcinomas 
than normal ovaries, but was unable to distinguish between 
ovarian tumour tissues and metastasis (Hibbs et al. 2004). 
Various studies have suggested both tumour-promoting 
and suppressive roles of BMPs in tumour progression in a 
wide range of human tumours depending on the status of 
tumours and their microenvironment (Bach et al. 2017). 
Thus, the exact role of BMPs in ovarian cancer, and resist-
ance to platinum-based chemotherapeutic drugs, requires 
further investigation.
In conclusion, both the previous and the current ovar-
ian cancer patient-based studies indicate that calpain-2 
expression is adversely associated with overall survival, 
with calpain-4 and calpastatin expression also negatively 
associated with overall survival in the current study. In 
ovarian cancers, the calpain system has been confirmed 
to play an important role and influence patient outcome; 
however, the precise mechanisms whereby it exerts effects 
remain to be elucidated.
Table 3  Multivariate (Cox proportional hazard regression) analysis
Significant P values are indicated by bold type
Exp(B) is used to denote hazard ratio
Variables P value Exp (B) 95% Confidence 
interval for Exp 
(B)
Lower Upper
Multivariate (overall survival) (239 patients)
 Age (median 62) 0.225 1.253 0.870 1.805
 Grade 0.177 1.445 0.847 2.465
 FIGO stage 0.001 1.513 1.192 1.919
 Histological subtypes 0.833 0.983 0.836 1.155
 Platinum sensitivity < 0.001 3.142 2.024 4.879
 Tumour residue 0.029 1.298 1.028 1.639
 Calpastatin expression 0.061 0.711 0.498 1.015
Multivariate (overall survival) (238 patients)
 Age (median 62) 0.059 1.404 0.987 1.998
 Grade 0.138 1.527 0.873 2.673
 FIGO stage < 0.001 1.540 1.209 1.962
 Histological subtypes 0.959 1.004 0.855 1.180
 Platinum sensitivity < 0.001 3.272 2.107 5.082
 Tumour residue 0.031 1.283 1.023 1.610
 Calpain-2 expression 0.070 1.524 0.967 2.404
Multivariate (overall survival) (239 patients)
 Age (median 62) 0.164 1.296 0.900 1.867
 Grade 0.201 1.427 0.828 2.462
 FIGO stage 0.001 1.497 1.178 1.904
 Histological subtypes 0.801 0.979 0.832 1.152
 Platinum sensitivity < 0.001 3.088 1.987 4.798
 Tumour residue 0.023 1.303 1.037 1.639
 Calpain-4 expression 0.232 0.793 0.542 1.160
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Fig. 4  Kaplan–Meier survival 
curves showing combinato-
rial calpains and calpastatin 
expression-related overall 
survival. a survival analysis 
of combinatorial calpain-1 
and calpastatin expression of 
tumours. b survival analysis 
of combinatorial calpain-2 
and calpastatin expression of 
tumours. c survival analysis 
of combinatorial calpain-4 
and calpastatin expression of 
tumours. d Survival analysis 
of combinatorial calpain-1 
and calpain-2 expression of 
tumours. e Survival analysis of 
combinatorial calpain-1 and cal-
pain-4 expression of tumours. f 
Survival analysis of combinato-
rial calpain-2 and calpatin-4 
expression of tumours. Signifi-
cance was determined using the 
log-rank test
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Fig. 5  Western blot quantification of protein expression in ovarian 
cancer cell lines. Representative western blots of three independent 
experiments are presented. Open arrows indicate β-actin (42  kDa) 
which was used as the loading control. Black arrows indicate a cal-
pastatin (between 100 and 120  kDa), b calpain-1 (82  kDa), c cal-
pain-2 (80  kDa) and d calpain-4 (28-kDa), respectively. Lane M: 
protein marker, Lane 1: A2780, Lane 2: A2780-cis, Lane 3: SKOV3, 
Lane 4: PEO1, and Lane 5: PEO4. Graphical representation of pro-
tein levels of e calpastatin, f calpain-1, g calpain-2 and h calpain-4 in 
ovarian cancer cell lines relative to β-actin. Data represent the aver-
age ± standard deviation of three independent experiments. Statistical 
significance was determined by one-way ANOVA and is indicated by 
asterisk. *P < 0.05, **P < 0.01 and ***P < 0.001
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